Overall, these findings reveal a critical interplay between adipocyte‐mediated metabolic reprogramming and EIF3H‐mediated YAP proteolytic control, offering promising therapeutic strategies to mitigate the adverse effects of obesity on TNBC progression. The gene discussed is YAP1; the disease is obesity disorder.